FDA
-
-
-
-
-
-
-
BioCryst licenses navenibart to Neopharmed Gentili for European market
-
-
-
-
-
-
-
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
-
-
-
-
-
-
-
BioCryst presents pediatric HAE data at medical conference
-
-
-
-
-
-
-
BioCryst chief research officer to depart September 1
-
-
-
-
-
-
-
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
-
-
-
-
-
-
-
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
-
-
-
-
-
-
-
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
-
324,696 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

